$1.800
+0.030 (+1.69%)At close
CUPR News
CUPR Events
Cuprina Acquires East Coast Podiatry Centre and Orchard Clinic for Approximately S$4.0M
Cuprina announced that it has entered into Sale and Purchase Agreements to acquire the entire issued and paid-up share capital of East Coast Podiatry Centre, which operates East Coast Podiatry Clinic, the leading podiatry-focused chain in Singapore; and Orchard Clinic Management, which operates Orchard Clinic, ORC, a Singapore women's health and wellness clinic, through its direct wholly-owned subsidiary, Cuprina Holdings. Under the SPAs, an aggregate purchase consideration of approximately S$4.0M will be satisfied as follows S$3.0M in cash, comprising approximately S$0.5M paid upon execution, S$1.35M payable upon closing, and S$1.15M in deferred cash consideration payable over a two-year period; and S$1.0M in Class A ordinary shares of the Company
R. F. Lafferty & Co. Acts as Underwriter
R. F. Lafferty & Co. is acting as the underwriter for the offering.
Cuprina Holdings Receives FDA Clearance for Medifly Maggots
Cuprina Holdings announced that an indirectly wholly-owned subsidiary of the company, Cuprina Pte. has received 510 clearance from the FDA for Medifly Maggots, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy.
Cuprina Holdings Completes Reverse Stock Split, Requests Nasdaq Hearing
Cuprina Holdings announced that it completed a reverse stock split on May 27, 2026, and requested a hearing before the Nasdaq Hearings Panel, in response to a staff determination letter received on May 27, 2026, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. The Letter notified the company that, due to the company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined that company's securities will be scheduled for delisting from Nasdaq unless the company requests an appeal of the Determination to a Panel. On November 26, 2025, the company received a notice from Nasdaq, notifying the company that based upon the closing bid price of its securities for the last 30 consecutive business days preceding the Notice, the company was not in compliance with the Minimum Bid Requirement. In accordance with Listing Rule 5810(c)(3)(a), the Notice provided the company a period of 180 calendar days from the date of the Notice, or until May 26, 2026, to regain compliance with the Minimum Bid Requirement. According to the Letter, the company had not regained compliance with the Minimum Bid Requirement as of May 26, 2026. Unless the company requests an appeal of the Determination by June 3, 2026 to the Panel, the company's securities will be suspended at the opening of business on June 5, 2026, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the company's securities from listing and registration on Nasdaq. The company has proactively completed the share consolidation on May 27, 2026, which is expected to bring the company's bid price into compliance with the Minimum Bid Requirement. The company remains committed to maintaining its Nasdaq listing and will provide its shareholders with material updates when they are available.
Cuprina Holdings Implements 1-for-8 Share Consolidation
Cuprina Holdings announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares and Class B ordinary shares, effective on or around May 27. Beginning with the opening of trading on or around May 27, the company's Class A shares will begin trading on a post-share consolidation basis on the Nasdaq Capital Market under the same symbol " CUPR ", but under a new CUSIP number of G2592E110. "This action is an important step toward maintaining our Nasdaq listing and enhancing the Company's long-term financial flexibility. This approval reflects our shareholders' support for strengthening Cuprina's capital markets position as we continue advancing our biomedical and collagen-based technology portfolio," said Cuprina Chief Executive Officer David Quek.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.